Table 1:

Baseline demographic, serum, and clinical data for PD and statin subgroup subjects.

	Total Cohort	Statin non-users	Statin users
			Total	Lipophilic	Hydrophilic
Demographics
Subjects, n	125	91	34	24	10
Age, y	67.7 (9.3)	67.9 (9.6)	67.2 (8.5)	67.4 (8.6)	66.7 (8.9)
Gender, n (M/F)	69/56	50/41	19/15	14/10	5/5
Education, y	14.6 (2.8)	14.5 (2.9)	15.1 (2.5)	15.1 (2.5)	14.9 (2.6)
Laboratory
Cholesterol, mg/dL	182.3 (37.4)	187.1 (37.1)	169.7 (35.5)	167.2 (34.8)	175.9 (38.3)
LDL, mg/dL	108.1 (29.9)	113.2 (29.5)	94.6 (26.9)	92.5 (27.5)	99.6 (26.1)
HDL, mg/dL	52.9 (16.0)	52.4 (15.3)	54.3 (17.7)	56.2 (18.4)	49.9 (16.0)
Clinical Measurements
Disease Duration, y	6.4 (6.7)	6.2 (6.7)	7.0 (6.8)	7.4 (7.2)	6.0 (5.9)
LEDD, mg	644 (470)	648 (494)	631 (404)	598 (364)	707 (497)
UPDRS-total	53.2 (33.9)	55.3 (35.1)	47.7 (30.2)	50.6 (34.2)	40.8 (17.0)
UPDRS-I	10.3 (7.3)	11.0 (7.8)	8.4 (5.3)	9.3 (5.5)	6.1 (4.2)
UPDRS-II	11.1 (9.9)	11.9 (10.5)	8.9 (7.7)	9.9 (8.5)	6.6 (4.8)
UPDRS-III	29.6 (19.5)	29.9 (19.0)	28.9 (21.1)	30.4 (23.1)	25.4 (15.8)
UPDRS-IV	2.3 (3.3)	2.6 (3.6)	1.5 (2.3)	1.0 (1.7)	2.7 (3.1)
MoCA	23.6 (4.4)	24.3 (3.7)	25.1 (2.7)	25.6 (2.2)	24.3 (3.3)
UPSIT	19.1 (7.6)	19.1 (7.4)	19.1 (8.3)	18.3 (8.0)	20.7 (9.1)
Susceptibility R2* (1/s)	28.0 (4.1)	28.3 (4.0)	27.3 (4.4)	26.9 (3.6)	27.9 (5.7)

Data represent mean with standard deviations in parentheses unless otherwise specified. Abbreviations: M=male; F=female; y=years; LEDD=Levodopa equivalent daily dosage; MoCA=Montreal Cognitive Assessment; UPDRS=Unified Parkinson’s Disease Rating Scale, I=non-motor experiences of daily living, II=motor experiences of daily living, III=motor examination; IV=motor dysfunction; total=sum of UPDRS parts I-IV; UPSIT=University of Pennsylvania Smell Identification Test.